NIH finds new bladder cancer targets

Share this article:

The Cancer Genome Atlas Research Network, a collaboration between two National Institutes of Health groups, has identified new drug targets for bladder cancer that invades the bladder's muscle, a condition the group notes is the deadliest form of the disease, and for which there is no approved second-line therapy.

Researchers also found that the cancer has some genetics in common with some breast, lung, and head & neck cancers, which could help identify new ways to approach the disease.

Among the findings: 

  • Recurrent mutations in 32 genes, nine of which were not previously known to be “significantly mutated"
  • Potential drug targets in 69% of the evaluated tumors
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.